It turns out that AbbVie is only interested in buying Gilgamesh's lead drug programme, a psychedelic candidate for major ...

Despite being a rare disease impacting less than a million people worldwide, gMG treatment is an increasingly crowded market, ...

Nucleus RadioPharma, the radiopharmaceutical-focused contract developing and manufacturing organisation founded by Eclipse ...

A new study published in the Nature journal of Mental Health Research shows powerful real-world evidence for the efficacy of ...

Washington DC-based Vanda was sent a complete response letter (CRL) from the FDA in 2019, rejecting Hetlioz (tasimelteon) for ...

The positive data from the Phase 3 Denali trial showed that NCX 470, a nitric oxide-donating bimatoprost eyedrop formulation, ...

After UK Health Secretary Wes Streeting sent a letter to the pharma industry, warning that he would withdraw from ...

And while pharma marketing agencies are embracing AI like everyone else, most are using AI tools on a case-by-case basis to ...

Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...

Johnson & Johnson has filled in some of the details of its $55 billion investment in US facilities announced earlier this ...

Among the plans will be greater first-line use of SGLT-2 inhibitors or 'gliflozin' drugs, which are mainly used second-line ...

Mindler has taken ownership of the UK company, which has been providing digitally delivered talking therapies to the NHS for ...